Abstract：【Objective】 To investigate the clinical effects of irinotecan combined with doxorubicin in patients with nasopharyngeal carcinoma and the influence of T cell subsets in peripheral blood. 【Methods】 A total of 72 patients with nasopharyngeal carcinoma random were divided into the conventional drug group (A group, n=36) and the combination group (B group, n=36). Both groups were treated with radiotherapy. A group was treated with cisplatin plus 5-fluorouracil. B group was treated with irinotecan combined with doxorubicin. A course of treatment contained 21 days and the whole procedure have 4 consecutive courses. The short-term efficacy, levels of peripheral blood T lymphocyte subsets and the incidence of toxic side effects were compared between the two groups. 【Results】 The short-term efficacy rate of the B group was 55.56% (20/36), which was higher than that of the A group 41.67% (15/36, P<0.05). The levels of CD3+, CD4+ and CD4+/CD8+ in the B group after treatment were higher than those in the A group (P<0.05), while CD8+ level was lower in the A group (P<0.05).The incidence of red blood cell reduction, thrombocytopenia, myelosuppression, abnormal electrocardiogram and digestive tract reaction during the treatment in the B group was lower than that in the A group (P<0.05). 【Conclusion】 The combination treatment of irinotecan and doxorubicin in patients with nasopharyngeal carcinoma can obtain higher short-term effects, improve the peripheral blood T-cell subsets, and have a low incidence of side effects. It is worthy of popularization and application.
陈杨. 伊立替康和多柔比星联合治疗鼻咽癌的疗效及对患者外周血T细胞亚群的影响[J]. 医学临床研究, 2020, 37(8): 1151-1153.
CHEN Yang. Efficacy of Irinotecan Combined with Doxorubicin in Treatment of Nasopharyngeal Carcinoma and Influence on Peripheral Blood T Cell Subsets. JOURNAL OF CLINICAL RESEARCH, 2020, 37(8): 1151-1153.
[1] 杨红丽,王栢耀,袁亚维.抑制Polo样激酶1对鼻咽癌细胞辐射敏感性的影响[J].中国肿瘤生物治疗杂志,2017,24(3):222-229.
[2] 李欣,黄俊明,陈美芬,等.白杨素联合喜树碱促进鼻咽癌细胞CNE2凋亡作用研究[J].中草药,2016,47(12):2130-2136.
[3] Wasim L, Chopra M. Abstract B51: The pan deacetylase inhibitor panobinostat shows cytotoxic activity as monotherapy and synergism with topoisomerase inhibitors in cervical cancer cells[J].Cancer Res,2016, 76(2 Supplement):B51.
[4] 高琳,陆贞,高笙刚,等.鼻咽癌患者放疗期医院感染的危险因素分析及预防对策[J].中华医院感染学杂志,2017,27(11):2565-2568.
[5] 施海明,尤慧华,诸葛盼,等.鼻咽癌患者放疗后医院感染的危险因素分析[J].中华医院感染学杂志,2016,26(13):3052-3054.
[6] Xu T, Ou X, Shen C, et al. Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma[J].Anticancer Drugs,2016, 27(1):66.
[7] Xia J, Xia K, Feng Y, et al. The Combination of Suicide Gene Therapy and Radiation Enhances the Killing of Nasopharyngeal Carcinoma Xenographs[J].J Radiat Res,2004, 45(2):281-289.
[8] 胡琛,周维国,梁晨阳,等.CD44和CD24在鼻咽癌细胞系HK-1中调控STAT3发生磷酸化的分子机制研究[J].标记免疫分析与临床,2017,24(4):438-442.
2020, Vol. 37 
